The Indian Pharmacopeia Commission (IPC) in association with United States Pharmacopeial convention (USP) is planning to organise the 12th Science and Standards Symposium on April 16-17 in New Delhi.

Sources from USP Hyderabad revealed that the meeting is designed to support a science based dialogue to address relevant topics affecting pharmaceutical regulators and manufacturers in the region. The other important objective of the symposium is to create more awareness about the safety and access to quality medicines.

The Symposium is expected to offer both plenary sessions and separate tracks focusing on chemical medicines and biological medicines. Kiran Mazumdar Shaw, managing director of Biocon is expected to take part in the event.

Evolution of validation practices (e.g. Analytical Target Profiles, linearity) and discussion on bio-similarity and interchangeability will be among the main topics of focus in the Chemical Medicine and Biological Medicine sessions respectively.

New USP general chapters on bioassays and a number of presentations on technical and regulatory issues surrounding vaccines will also be discussed during the two day symposium.

The symposium is expected to benefit a range of professionals from across the pharma and biotechnology industry in the country. Working professionals in pharmaceutical quality control, quality assurance, regulatory affairs, compendia affairs and production can reap a great deal of knowledge pertaining to contemporary research and quality management issues in the industry.

Others who can take part in the symposium include laboratory managers, analysts, technicians, research associates and project leaders. Apart from manufacturers, exporters and importers of medicines and their ingredients, the meeting is also expected to witness the presence of policy makers, academicians, and others interested in compendial affairs. The meeting is an apt platform for those working in the biosimilars, vaccines and biotherapeutic industries.